Seeking Alpha
25 Oct 2026, 18:56 UTC · 2h ago
Ionis Pharmaceuticals: Compelling Long-Term Commercial Upside
Impact · against what's priced in
The article provides no new catalysts for Ionis Pharmaceuticals, as the independent launches of Zanvastro and Tryngolza and the company's cash burn are already accounted for in the current valuation. The outlook remains dependent on the Pelacarsen trial and actual prescription volume, which this commentary does not update.
- IONS+0.00
Already priced in
- The price assumes
The recent FDA approval of Zanvastro for Alexander disease and Tryngolza for severe hypertriglyceridemia, both now factored in as baseline assets.
The mentions of independent launches for Zanvastro and the expanded indication for Tryngolza simply confirm baseline assets the market has already integrated into the price.
What IONS's price assumes · Sep 14
